Pamela Wedel

457 total citations
14 papers, 387 citations indexed

About

Pamela Wedel is a scholar working on Infectious Diseases, Epidemiology and Organic Chemistry. According to data from OpenAlex, Pamela Wedel has authored 14 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 6 papers in Epidemiology and 2 papers in Organic Chemistry. Recurrent topics in Pamela Wedel's work include Antifungal resistance and susceptibility (7 papers), Nail Diseases and Treatments (3 papers) and Fungal Infections and Studies (3 papers). Pamela Wedel is often cited by papers focused on Antifungal resistance and susceptibility (7 papers), Nail Diseases and Treatments (3 papers) and Fungal Infections and Studies (3 papers). Pamela Wedel collaborates with scholars based in United States, Netherlands and Israel. Pamela Wedel's co-authors include Michael R. Hodges, Steven D. Targum, Maurizio Fava, Karen Joy Shaw, William G. Kramer, Carrolee Barlow, Margaret Tawadrous, Robert S. Mansbach, Fred H. Gage and José A. Vázquez and has published in prestigious journals such as Gastroenterology, Antimicrobial Agents and Chemotherapy and Molecular Psychiatry.

In The Last Decade

Pamela Wedel

12 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pamela Wedel United States 10 214 174 78 49 49 14 387
Eduardo Vázquez-Valls Mexico 12 64 0.3× 62 0.4× 57 0.7× 88 1.8× 28 0.6× 28 441
Bernardo Stutz United States 13 229 1.1× 181 1.0× 71 0.9× 157 3.2× 31 0.6× 17 816
Sandra Recio Spain 10 368 1.7× 294 1.7× 46 0.6× 14 0.3× 148 3.0× 15 627
Greer McKendrick United States 10 45 0.2× 137 0.8× 69 0.9× 162 3.3× 16 0.3× 23 420
Hui‐Chun Li China 15 56 0.3× 39 0.2× 71 0.9× 64 1.3× 88 1.8× 48 701
Xiangpeng Ren China 10 46 0.2× 65 0.4× 60 0.8× 63 1.3× 9 0.2× 10 404
Tianye Jia China 11 129 0.6× 17 0.1× 28 0.4× 33 0.7× 26 0.5× 47 788
Kumiko Yamada Japan 13 53 0.2× 25 0.1× 77 1.0× 30 0.6× 12 0.2× 42 501
Sarah Bridge United Kingdom 8 68 0.3× 74 0.4× 27 0.3× 191 3.9× 29 0.6× 8 378
Matthew Grunewald United States 9 278 1.3× 33 0.2× 26 0.3× 32 0.7× 58 1.2× 9 610

Countries citing papers authored by Pamela Wedel

Since Specialization
Citations

This map shows the geographic impact of Pamela Wedel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Wedel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Wedel more than expected).

Fields of papers citing papers by Pamela Wedel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela Wedel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Wedel. The network helps show where Pamela Wedel may publish in the future.

Co-authorship network of co-authors of Pamela Wedel

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Wedel. A scholar is included among the top collaborators of Pamela Wedel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Wedel. Pamela Wedel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Jairath, Vipul, Silvio Danese, Geert D’Haens, et al.. (2025). OP31 Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis. Journal of Crohn s and Colitis. 19(Supplement_1). i62–i63. 4 indexed citations
2.
3.
4.
Pappas, Peter G., José A. Vázquez, Ilana Oren, et al.. (2023). Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. Journal of Antimicrobial Chemotherapy. 78(10). 2471–2480. 37 indexed citations
5.
Hodges, Michael R., Pamela Wedel, Karen Joy Shaw, et al.. (2023). Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 67(4). e0162322–e0162322. 32 indexed citations
6.
Vázquez, José A., Peter G. Pappas, Kenneth D Boffard, et al.. (2023). Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial. Antimicrobial Agents and Chemotherapy. 67(5). e0141922–e0141922. 54 indexed citations
7.
Pappas, Peter G., Bart Jan Kullberg, José A. Vázquez, et al.. (2020). 147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial. Open Forum Infectious Diseases. 7(Supplement_1). S203–S204. 16 indexed citations
8.
Bulpa, Pierre, Galia Rahav, Ilana Oren, et al.. (2020). 1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial. Open Forum Infectious Diseases. 7(Supplement_1). S605–S605. 7 indexed citations
9.
Hodges, Michael R., Karen Joy Shaw, Robert S. Mansbach, et al.. (2017). Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability. Open Forum Infectious Diseases. 4(suppl_1). S534–S534. 42 indexed citations
10.
Hodges, Michael R., et al.. (2017). First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects. Open Forum Infectious Diseases. 4(suppl_1). S526–S526. 36 indexed citations
11.
Targum, Steven D., Pamela Wedel, & Maurizio Fava. (2015). Changes in cognitive symptoms after a buspirone–melatonin combination treatment for Major Depressive Disorder. Journal of Psychiatric Research. 68. 392–396. 25 indexed citations
12.
Steele, John, Gregory D. Clemenson, R.A. Gadient, et al.. (2014). Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer mouse. Molecular Psychiatry. 19(11). 1235–1242. 52 indexed citations
13.
Targum, Steven D., Pamela Wedel, Jill O. Robinson, et al.. (2013). A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder. Journal of Psychiatric Research. 47(7). 944–954. 26 indexed citations
14.
Fava, Maurizio, Steven D. Targum, Andrew A. Nierenberg, et al.. (2012). An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery. Journal of Psychiatric Research. 46(12). 1553–1563. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eduardo Vázquez-Valls Breakdown of academic impact, for papers by Bernardo Stutz Breakdown of academic impact, for papers by Sandra Recio Breakdown of academic impact, for papers by Greer McKendrick Breakdown of academic impact, for papers by Hui‐Chun Li Breakdown of academic impact, for papers by Xiangpeng Ren Breakdown of academic impact, for papers by Tianye Jia Breakdown of academic impact, for papers by Kumiko Yamada Breakdown of academic impact, for papers by Sarah Bridge Breakdown of academic impact, for papers by Matthew Grunewald
Rankless by CCL
2026